晚期非小细胞肺癌维持治疗的研究进展  

Maintenance therapy in advanced non-small cell lung cancer

作　　者：程婷婷[1] 杨谨[1] 

机构地区：[1]西安交通大学医学院第一附属医院肿瘤内科,陕西西安710061

出　　处：《中华肿瘤防治杂志》2011年第20期1651-1655,共5页Chinese Journal of Cancer Prevention and Treatment

摘　　要：目的:总结维持治疗在晚期非小细胞肺癌中的研究进展,探讨维持治疗的意义。方法:应用PubMed和CNKI期刊全文数据库检索系统,以"NSCLC maintenancetherapy及非小细胞肺癌,维持治疗"为关键词,共检索到2001-2011年相关文献284篇,纳入分析25篇。结果:维持治疗是近年来为延长晚期NSCLC患者生存期并提高其生存质量而出现的新的治疗观点,目前已有多项临床试验证实标准一线化疗结束使疾病获得控制后,继续给予维持治疗可以显著延长患者的无疾病进展生存期(progression-free survival,PFS),部分药物可以显著延长总生存(overall survival,OS),患者耐受良好。结论:维持治疗可以使晚期NSCLC患者获益,但是其最终疗效和患者的病理类型、EGFR突变状况、体力状况和对药物的耐受情况密切相关,结合患者的实际情况,进行个体化治疗,是NSCLC患者未来治疗的方向。OBJECTIVE： To summarize the advances of main tenanee therapy in NSCLC, and discuss the significance of this therapeutic method. METHODS： The full text database of PubMed and CNKI were searched, and the words＂NSCLC, maintenance therapy＂ were used as key words. Totally 284 related articles were retrieved between the year of 2001 and 2011 in all, then 25 were analyzed. RESULTS： Maintenance therapy emerged as a new viewpoint in these years in order to prolong the overall survival and to improve quality of life for patients with advanced NSCLC. At present,many clinical trials have demonstrated that the patients with advanced NSCLC who achieved CR,PR and SD after the first line chemotherapy could be significantly prolonged Progression-free survival（PFS） and overall survival（OS） if they received continued maintenance therapy. The tolerance was well. CONCLUSIONS： Patients with advanced NSCLC can benefit from the maintenance therapy. However, the final therapeutic effect is closely related to the pathological type, EGFR mutation, physical condition and tolerance to chemotherapy of each patient. Individual therapy that corn hines with the practical status of each patient is considerated to be the future direction.

关 键 词：癌 非小细胞肺/药物疗法 治疗 综述文献 

分 类 号：R734.2[医药卫生—肿瘤]